Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Jens Kleesiek
No abstract text is available yet for this article.
August 2023: RöFo: Fortschritte Auf Dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
#22
JOURNAL ARTICLE
Ilias Tsiflikas
No abstract text is available yet for this article.
August 2023: RöFo: Fortschritte Auf Dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
#23
JOURNAL ARTICLE
Hervé Ghesquières
No abstract text is available yet for this article.
June 2023: La Revue du Praticien
#24
JOURNAL ARTICLE
Christine Rousset-Jablonski
No abstract text is available yet for this article.
June 2023: La Revue du Praticien
#25
JOURNAL ARTICLE
Jean-Marie Michot, Julien Lazarovici
TOXICITY OF TARGETED THERAPIES AND IMMUNOTHERAPY WITH CHECKPOINT INHIBITORS IN HODGKIN LYMPHOMA. In patients at increased risk of recurrence or progression after autotransplantation, or in cases of relapse after autotransplantation or after at least two lines of treatment when intensive multidrug therapy is no longer a treatment option, targeted anti-CD30 therapy with brentuximab vedotin may be proposed. Brentuximab vedotin is a monoclonal antibody directed against CD30 and coupled with an anti-microtubule cytotoxic agent, monomethyl auristatin E (MMAE)...
June 2023: La Revue du Praticien
#26
JOURNAL ARTICLE
Hervé Ghesquières
CHALLENGES OF LONG-TERM FOLLOW UP FOR HODGKIN LYMPHOMA SURVIVORS. Challenge of Hodgkin lymphoma care is to obtain a high level of curability and minimize acute toxicities and long-term complications of chemotherapy and radiotherapy. A specific long-term multi-disciplinary follow-up should be organize with an important place of general practitioners. The follow-up concerns the risk of second cancer especially breast cancer and treatment-related cardiovascular diseases. In addition, a careful attention concerns some possible negative effects of the disease and treatments on psychosocial status and quality of life of Hodgkin lymphoma survivors...
June 2023: La Revue du Praticien
#27
JOURNAL ARTICLE
Bénédicte Deau Fischer
2ND AND SUBSEQUENT LINE TREATMENTS. Patients who fail first-line treatment can be cured with salvage chemotherapy followed by intensified therapy and hematopoietic stem cell autotransplantation. This treatment strategy is feasible for patients who are eligible based on their age, with chemosensitive disease and associated comorbidities. There is no standard of care for salvage chemotherapy, but patients who are in complete remission prior to transplantation have the best prognosis. Combinations of salvage therapy, including new molecules, have shown interesting results, but without comparative trials...
June 2023: La Revue du Praticien
#28
JOURNAL ARTICLE
Cédric Rossi, Olivier Casasnovas
FRONTLINE THERAPY FOR CLASSICAL HODGKIN LYMPHOMA PATIENTS. Upfront first-line chemotherapy is indicated for all features of classical Hodgkin's lymphoma, followed by involved node radiotherapy in early stages; the ABVD protocol (doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine) is the international standard of care. The 7-agent BEACOPP protocol (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine (Oncovin), procarbazine, prednisone) is used in advanced stages in its «escalated» version (BEAesc)...
June 2023: La Revue du Praticien
#29
JOURNAL ARTICLE
Hervé Ghesquières
DIAGNOSIS AND STAGING OF HODGKIN LYMPHOMA. Hodgkin lymphoma (HL) is composed of two distinct disease entities: classical HL (cHL) and nodular lymphocyte predominant HL (NLPHL). NLPHL is a rare entity with a specific therapeutic management. The subgroups of cHL are nodular sclerosis, mixed cellularity, lymphocyte depletion and lymphocyte-rich HL. The initial diagnosis of HL is made by a biopsy to analyze with accuracy the architecture of the lymph node. Most HL patients present with supradiaphragmatic lymphadenopathy...
June 2023: La Revue du Praticien
#30
JOURNAL ARTICLE
Hervé Ghesquières
EPIDEMIOLOGY OF CLASSICAL HODGKIN LYMPHOMA. Classical Hodgkin lymphoma is a rare neoplasia but represents one of the most common cancers in adults younger than 40 years old. Epidemiology of Hodgkin lymphoma remains fascinating with specific incidence patterns depending of age, socio-economic status, histological subtypes and Epstein-Barr virus (EBV) tumor status. These findings are in favor of several diseases with different pathogenesis. A better understanding of biological specificities of some Hodgkin lymphoma subgroups such as those presenting by older patients might be helpful to improve treatment strategies and outcome...
June 2023: La Revue du Praticien
#31
JOURNAL ARTICLE
Christophe Fermé
THE HISTORY OF HODGKIN LYMPHOMA. Hodgkin lymphoma was initially considered to be caused by infectious agents. The Hodgkin and Reed-Sternberg tumor cells are derived from mature B cells and transforming events were identified. Staging laparotomy has been discontinued for clinical evaluation with the progress of medical imaging. For seven decades, clinical trials have allowed to define risk factors, to improve standard treatments with the optimal use of chemotherapy and radiotherapy. A risk adapted strategy and early response to chemotherapy are mandatory to reduce long-term consequences of treatment...
June 2023: La Revue du Praticien
#32
JOURNAL ARTICLE
T Escoda, M Garcia, C Stavris, S Genot, F Retornaz, L Chiche, V Brunel
No abstract text is available yet for this article.
July 12, 2023: La Revue de Médecine Interne
#33
JOURNAL ARTICLE
U J Chilaka, N Benedict, C Kingsley, A Clara, E Geoffery, E Chinedum, N P Onyinye
BACKGROUND: Venous thromboembolism (VTE) is a cause of increased morbidity and mortality in cancer patients. VTE is the second leading cause of death in cancer patients. Risk assessment models have been developed to identify patients at risk of VTE for thromboprophylaxis. Risk scores of patients in our environment have not been adequately investigated. OBJECTIVE: The study evaluates the association of thrombotic risk assessment scores (using the modified Khorana risk assessment tool) and soluble P-selectin levels with thrombotic events in patients with lymphoid cancer...
May 27, 2023: West African Journal of Medicine
#34
JOURNAL ARTICLE
Elif Durak Ediboğlu, Dilek Solmaz, Sermin Özkal, Nezahat Karaca Erdoğan, Servet Akar
Upper respiratory tract involvement is common in patients with granulomatosis with polyangiitis (GPA), but malignancies should be kept in mind in the differential diagnosis. A 68-year-old man was referred to rheumatology to investigate for GPA after nasal excisional biopsy. After careful radiologic and pathologic assessment, he was diagnosed with peripheral T‑cell lymphoma, nasal type. This is a rare case of T‑cell lymphoma in a patient who was referred as GPA.
May 26, 2023: Zeitschrift Für Rheumatologie
#35
JOURNAL ARTICLE
Marie Frischkorn, Michael Fortelny, Malgorzata Ciurkiewicz, Johannes Krüger, Doris Jahn-Falk
The presented report describes a case of sporadic bovine leukosis and its disease progression in an 8-week old, male cross-breed calf (Red Holstein Fleckvieh). The calf was initially presented due to suspect pulmonary infection. However, generalized enlargement of the subcutaneous lymph nodes was noticed, which is untypical for this disease. Based on the hematologic findings of highly increased numbers of lymphoblasts in peripheral blood as well as the sonographic examination of the lymph nodes, sporadic bovine leukosis was suspected...
April 2023: Tierärztliche Praxis. Ausgabe G, Grosstiere/Nutztiere
#36
JOURNAL ARTICLE
A Gueiderikh, M Ung, J Lazarovici, A Danu, D Ghez, K Saleh, M Dragani, N Noël, C Bigenwald, C Willekens, V Ribrag, J-M Michot, V Martin
PURPOSE: Follicular lymphoma (FL) is one of the most common lymphoma. Occasionally, FL is associated with tumoral epidural compression and management of these patients remain poorly codified. This study aims to report incidence, clinical characteristics, management and outcomes of patients with FL and tumoral epidural compression. MATERIAL AND METHODS: Observational, retrospective cohort study of adult patients with FL and epidural tumor compression, treated in a French Institute over the last 20 years (2000-2021)...
May 6, 2023: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
#37
JOURNAL ARTICLE
Benjamin Podvin, Jean-Baptiste Bossard, Christine Pucalowski, Geoffrey Bouchez
No abstract text is available yet for this article.
May 5, 2023: Annales de Biologie Clinique
#38
EDITORIAL
Falko Fend
No abstract text is available yet for this article.
May 2023: Pathologie (Heidelb)
#39
REVIEW
Falko Fend, Leticia Quintanilla-Martinez, Wolfram Klapper
Recently, two new classifications were released: the International Consensus Classification (ICC) drafted by the Clinical Advisory Committee and the short version of the 5th Edition of the WHO classification of hematolymphoid tumors. In light of new clinical, morphological, and molecular data, both classifications also revised the classification of peripheral T‑cell lymphomas. In addition to relatively minor changes in terminology and disease definitions, both new classifications mirror the considerable gain of knowledge on the genetic alterations of different T‑cell lymphoma entities...
April 28, 2023: Pathologie (Heidelb)
#40
JOURNAL ARTICLE
Adèle de Masson, Marie Beylot-Barry, Caroline Ram-Wolff, Jean-Baptiste Mear, Stéphane Dalle, Michel d'Incan, Saskia Ingen-Housz-Oro, Corentin Orvain, Julie Abraham, Olivier Dereure, Amandine Charbonnier, Jérôme Cornillon, Christine Longvert, Stéphane Barete, Serge Boulinguez, Ewa Wierzbicka-Hainaut, François Aubin, Marie-Thérèse Rubio, Marc Bernard, Aline Schmidt-Tanguy, Roch Houot, Anne Pham-Ledard, David Michonneau, Pauline Brice, Hélène Labussière-Wallet, Jean-David Bouaziz, Florent Grange, Hélène Moins-Teisserenc, Katayoun Jondeau, Laurence Michel, Samia Mourah, Maxime Battistella, Etienne Daguindau, Michael Loschi, Alexandra Picard, Nathalie Franck, Natacha Maillard, Anne Huynh, Stéphanie Nguyen, Ambroise Marçais, Guillaume Chaby, Patrice Ceballos, Yannick Le Corre, Sébastien Maury, Jacques-Olivier Bay, Henri Adamski, Emmanuel Bachy, Edouard Forcade, Gérard Socié, Martine Bagot, Sylvie Chevret, Régis Peffault de Latour
BACKGROUND: Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. Case series have suggested that allogeneic haematopoietic stem cell transplantation (HSCT) might improve the prognosis of advanced-stage CTCLs. The objective of this study was to investigate the effect of allogeneic HSCT compared with non-HSCT therapy on the outcome of individuals with advanced-stage CTCLs. METHODS: In this prospective, multicentre, matched controlled trial, conducted at 30 hospitals, participants with advanced CTCLs were allocated treatment: if they had an available compatible related donor they were assigned to allogeneic HSCT, or if not they were allocated to non-allogeneic HSCT therapy...
June 10, 2023: Lancet
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
